One To Watch
Mineralys Therapeutics
Company Overview
A clinical-stage biopharmaceutical company pursuing FDA approval for lorundrostat, a highly selective aldosterone synthase inhibitor targeting treatment-resistant hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics trades on Nasdaq under MLYS and is advancing a single, well-characterized asset through a broad cardiorenal development program. The company's thesis is that aldosterone excess drives blood pressure that conventional antihypertensives cannot adequately control — and that a sufficiently selective inhibitor of its synthesis can address that root cause without the cortisol disruption that has limited earlier compounds in this class.
Headquarters and Global Presence
Mineralys is headquartered in Radnor, Pennsylvania. The company ran its pivotal Launch-HTN trial as a global, randomized, double-blind study, reflecting international enrollment ambitions, though its regulatory focus is currently anchored to the FDA.
Founding and History
CEO Jon Congleton guided Mineralys from early-stage private company to Nasdaq-listed biotech, a trajectory that reflects the rapid clinical de-risking of lorundrostat. The company filed its NDA for lorundrostat in hypertension, and the FDA accepted the submission with a PDUFA target action date of December 22, 2026 — placing Mineralys within months of a potential first commercial approval.
Therapy Areas and Focus
Mineralys is focused exclusively on cardiorenal conditions in which elevated aldosterone plays a causal role. Its primary indication is treatment-resistant or uncontrolled hypertension — a population where patients remain poorly controlled despite two to five concurrent antihypertensive medications, representing a substantial and underserved segment. Secondary development targets include chronic kidney disease with albuminuria and obstructive sleep apnea, both of which have established mechanistic links to aldosterone dysregulation.
Technology Platforms and Modalities
Lorundrostat inhibits CYP11B2, the enzyme responsible for aldosterone synthesis, with 374-fold selectivity over CYP11B1, the closely related cortisol synthase. That selectivity margin is the commercially important number: earlier aldosterone synthase inhibitors failed or stalled because insufficient enzyme selectivity produced cortisol suppression, generating a liability in stressed patients. With an observed half-life of 10-12 hours supporting once-daily oral dosing, and a 40-70% reduction in plasma aldosterone demonstrated in hypertensive participants, lorundrostat's pharmacological profile is designed to avoid the class's historical pitfalls.
Key Pipeline and Programs
Lorundrostat in uncontrolled hypertension is the lead program and the subject of the pending NDA. Launch-HTN was a global, randomized, double-blind, placebo-controlled Phase III trial enrolling adults whose systolic blood pressure remained uncontrolled on two to five antihypertensive agents. Patients received placebo, lorundrostat 50 mg once daily, or a titrated arm with the option to escalate to 100 mg at week six. Topline results demonstrated robust, durable, and statistically significant reductions in systolic blood pressure with a favorable safety profile. New analyses presented at ESH 2026 on May 30, 2026 extended those findings to participants with CKD, where lorundrostat also significantly reduced urine albumin-to-creatinine ratio — a secondary endpoint with direct implications for a future CKD indication. The Explore-OSA trial has generated topline data in obstructive sleep apnea, though detailed results from that program remain under evaluation, positioning OSA as a potential third indication if the aldosterone-OSA mechanistic hypothesis holds clinically.
Recent Developments
The FDA accepted the NDA for lorundrostat in hypertension and assigned a PDUFA date of December 22, 2026 — the defining near-term milestone for the company. New Phase III Launch-HTN sub-analyses presented at ESH 2026 in May 2026 showed meaningful blood pressure reductions and reduced albuminuria in participants with CKD, strengthening the case for a follow-on CKD filing. Topline Explore-OSA data in obstructive sleep apnea were also reported, broadening the potential label scope. CEO Jon Congleton gave an executive Q&A to The Pharma Letter in September 2025, setting out the company's development and commercialization strategy.
Key Personnel
Jon Congleton serves as Chief Executive Officer. He led Mineralys from private startup through Nasdaq listing and into NDA submission, providing continuity across the company's most consequential clinical and regulatory phases. Detailed biographical information on the chief scientific and financial officers is not available in current sources, though the company's clinical execution across multiple concurrent trials implies a seasoned development team.
Strategic Partnerships
No major licensing or co-development partnerships have been disclosed publicly. As Mineralys approaches its December 2026 PDUFA date with a single asset, the question of whether it commercializes independently or seeks a partner — particularly given the scale of the treatment-resistant hypertension market — is a live strategic variable that the company has not yet resolved publicly.
FAQ Section
Treatment-resistant hypertension — defined as uncontrolled blood pressure despite two or more antihypertensive agents — represents a population where existing drug classes have demonstrably failed. Aldosterone excess is disproportionately prevalent in this group, making it the most mechanistically coherent target for an aldosterone synthase inhibitor. Launch-HTN enrolled patients on two to five concurrent agents, positioning lorundrostat as an add-on therapy with a clear, differentiated patient selection rationale rather than a head-to-head challenger to first-line drugs.
CYP11B2 synthesizes aldosterone; CYP11B1 synthesizes cortisol. The two enzymes share roughly 93% structural homology, which is why earlier aldosterone synthase inhibitors inadvertently suppressed cortisol — creating adrenal insufficiency risk, particularly under physical stress, and ultimately limiting their development. Lorundrostat's 374-fold selectivity for CYP11B2 over CYP11B1 in vitro is designed to eliminate that liability. The clinical safety data from Launch-HTN, which showed a favorable profile over 12 weeks, suggests the selectivity margin is translating from bench to patient.
Mineralocorticoid receptor antagonists block the downstream receptor rather than suppressing aldosterone production at source. Spironolactone carries anti-androgenic side effects and hyperkalemia risk; finerenone is more selective but still works at the receptor level. Lorundrostat acts upstream by inhibiting synthesis, which means aldosterone levels themselves fall by 40-70% — potentially offering a cleaner cardiovascular and renal profile. Whether that mechanistic distinction translates into a clinically meaningful safety or efficacy advantage over finerenone in overlapping CKD populations is a question the eventual label and comparative data will need to answer.
Launch-HTN was a global, randomized, double-blind, placebo-controlled trial — the methodological gold standard — enrolling adults uncontrolled on two to five antihypertensive medications. The trial met its primary endpoint with statistically significant and clinically meaningful reductions in systolic blood pressure across both the fixed 50 mg and titrated 50/100 mg arms. Sub-analyses presented at ESH 2026 showed that participants with CKD and baseline albuminuria also experienced significant reductions in urine albumin-to-creatinine ratio, an endpoint relevant to renal disease progression. The 12-week treatment window means longer-term durability data will be closely watched post-approval.
The pipeline's cardiorenal logic extends aldosterone suppression into chronic kidney disease — where albuminuria reduction in Launch-HTN sub-analyses provides a clinical proof point — and into obstructive sleep apnea, where elevated aldosterone has been implicated in upper airway fluid retention. The Explore-OSA trial has generated topline data, though the OSA indication represents a less established aldosterone link than hypertension or CKD. If the OSA signal holds, lorundrostat's addressable population expands considerably beyond the already large treatment-resistant hypertension segment.
Mineralys is at the pivotal regulatory inflection point: the NDA is accepted, the PDUFA date is December 22, 2026, and the company is effectively a pre-commercial biotech awaiting its first approval. Phase III execution is complete for the lead indication, with CKD and OSA data adding label-expansion optionality. The immediate development priorities are managing the FDA review, preparing for potential commercialization, and determining whether the CKD albuminuria data from Launch-HTN warrants a standalone CKD filing.
The December 2026 PDUFA date concentrates nearly all near-term value creation into a single regulatory outcome. Key watchpoints include:
- FDA approval of lorundrostat for uncontrolled hypertension by December 22, 2026 — the binary event on which current valuation largely rests.
- Label scope: whether the FDA includes the CKD albuminuria data or confines the label narrowly to blood pressure reduction.
- Commercialization strategy: Mineralys has not announced a partner; launching independently in a competitive cardiorenal market requires substantial infrastructure.
- Explore-OSA data readout in full: if the signal is positive, it opens a materially larger patient population.
- Longer-term durability data: the 12-week Launch-HTN window leaves cardiovascular outcomes evidence as a post-approval gap that payers and guideline committees will notice.
Latest Mineralys Therapeutics News
Today's issue
| Headless Content Management with Blaze